Biotech Showcase™ 2017: Reinventing Arena to focus on Phase II clinical candidates

January 19, 2017
In the six months after joining Arena Pharmaceuticals as CEO, Dr. Amit Munshi has been busy: reducing the company’s commitment to obesity drug Belviq, which it has partnered with Eisai; spinning out the discovery research activities into a new company, Beacon Discovery; and prioritizing three Phase II programs with readouts in 2017. Munshi updates Mike Ward, global director of content at Informa Pharma Intelligence’s insights portfolio, on the company’s progress to date.
Previous Video
Biotech Showcase™ 2017: J&J poised to establish no-strings-attached JLABS outside America
Biotech Showcase™ 2017: J&J poised to establish no-strings-attached JLABS outside America

As Johnson & Johnson announced the establishment of its eighth JLABS facility, in collaboration with New Yo...

Next Video
Biotech Showcase™ 2017: ProNAI defects from oligos to DDR as Sierra Oncology
Biotech Showcase™ 2017: ProNAI defects from oligos to DDR as Sierra Oncology

Sierra Oncology president and CEO Dr. Nick Glover tells Mike Ward, Informa Pharma Intelligence insight glob...